FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206613789> ?p ?o ?g. }

• W4206613789 abstract "There have been many randomised trials of adjuvant tamoxifen among women with early breast cancer, and an updated overview of their results is presented.In this report, the Early Breast Cancer Trialists' Collaborative Group present their third 5-yearly systematic overview (meta-analysis) of treatment with tamoxifen.Trial identification procedures for the EBCTCG overviews have been described elsewhere. See under EBCTCG in the Breast Cancer Collaborative Review Group module.All randomised trials that began before 1990 and compared adjuvant tamoxifen for any duration versus no such treatment for women with early breast cancer.In 1995, information was sought on each woman in any randomised trial that began before 1990 of adjuvant tamoxifen versus no tamoxifen before recurrence. Information was obtained and analysed centrally on each of 37,000 women in 55 such trials, comprising about 87% of the worldwide evidence. Compared with the previous such overview, this approximately doubles the amount of evidence from trials of about 5 years of tamoxifen and, taking all trials together, on events occurring more than 5 years after randomisation.Nearly 8000 of the women had a low, or zero, level of the oestrogen-receptor protein (ER) measured in their primary tumour. Among them, the overall effects of tamoxifen appeared to be small, and subsequent analyses of recurrence and total mortality are restricted to the remaining women (18,000 with ER-positive tumours, plus nearly 12,000 more with untested tumours, of which an estimated 8000 would have been ER-positive). For trials of 1 year, 2 years, and about 5 years of adjuvant tamoxifen, the proportional recurrence reductions produced among these 30,000 women during about 10 years of follow-up were 21% (SD 3), 29% (SD 2), and 47% (SD 3), respectively, with a highly significant trend towards greater effect with longer treatment (2p<0.00001). The corresponding proportional mortality reductions were 12% (SD 3), 17% (SD 3), and 26% (SD 4), respectively, and again the test for trend was significant (2p=0.003). The absolute improvement in recurrence was greater during the first 5 years, whereas the improvement in survival grew steadily larger throughout the first 10 years. The proportional mortality reductions were similar for women with node-positive and node-negative disease, but the absolute mortality reductions were greater in node-positive women. In the trials of about 5 years of adjuvant tamoxifen the absolute improvements in 10-year survival were 10.9% (SD 2.5) for node-positive (61.4% vs 50.5% survival, 2p<0.00001) and 5.6% (SD 1.3) for node-negative (78.9% vs 73.3% survival, 2p<0.00001). These benefits appeared to be largely irrespective of age, menopausal status, daily tamoxifen dose (which was generally 20 mg), and of whether chemotherapy had been given to both groups. In terms of other outcomes among all women studied (ie, including those with ER-poor tumours), the proportional reductions in contralateral breast cancer were 13% (SD 13), 26% (SD 9), and 47% (SD 9) in the trials of 1, 2, or about 5 years of adjuvant tamoxifen. The incidence of endometrial cancer was approximately doubled in trials of 1 or 2 years of tamoxifen and approximately quadrupled in trials of 5 years of tamoxifen (although the number of cases was small and these ratios were not significantly different from each other). The absolute decrease in contralateral breast cancer was about twice as large as the absolute increase in the incidence of endometrial cancer. Tamoxifen had no apparent effect on the incidence of colorectal cancer or, after exclusion of deaths from breast or endometrial cancer, on any of the other main categories of cause of death (total nearly 2000 such deaths; overall relative risk 0.99 [SD 0.05]).For women with tumours that have been reliably shown to be ER-negative, adjuvant tamoxifen remains a matter for research. However, some years of adjuvant tamoxifen treatment substantially improves the 10-year survival of women with ER-positive tumours and of women whose tumours are of unknown ER status, with the proportional reductions in breast cancer recurrence and in mortality appearing to be largely unaffected by other patient characteristics or treatments." @default.
• W4206613789 created "2022-01-26" @default.
• W4206613789 creator A9999999999 @default.
• W4206613789 date "2001-01-22" @default.
• W4206613789 modified "2023-09-27" @default.
• W4206613789 title "Tamoxifen for early breast cancer" @default.
• W4206613789 cites W1562190372 @default.
• W4206613789 cites W175672528 @default.
• W4206613789 cites W1815807371 @default.
• W4206613789 cites W1961026612 @default.
• W4206613789 cites W1972083432 @default.
• W4206613789 cites W1978093589 @default.
• W4206613789 cites W1980557732 @default.
• W4206613789 cites W1991555263 @default.
• W4206613789 cites W2070202176 @default.
• W4206613789 cites W2098529121 @default.
• W4206613789 cites W2115118550 @default.
• W4206613789 cites W2147026385 @default.
• W4206613789 cites W2149944230 @default.
• W4206613789 cites W2154377786 @default.
• W4206613789 cites W2166631738 @default.
• W4206613789 cites W2171538830 @default.
• W4206613789 cites W2343407300 @default.
• W4206613789 cites W2901368272 @default.
• W4206613789 cites W4243828894 @default.
• W4206613789 cites W4293107555 @default.
• W4206613789 doi "https://doi.org/10.1002/14651858.cd000486" @default.
• W4206613789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11279694" @default.
• W4206613789 hasPublicationYear "2001" @default.
• W4206613789 type Work @default.
• W4206613789 citedByCount "29" @default.
• W4206613789 countsByYear W42066137892012 @default.
• W4206613789 countsByYear W42066137892015 @default.
• W4206613789 countsByYear W42066137892016 @default.
• W4206613789 countsByYear W42066137892017 @default.
• W4206613789 countsByYear W42066137892018 @default.
• W4206613789 countsByYear W42066137892020 @default.
• W4206613789 countsByYear W42066137892021 @default.
• W4206613789 countsByYear W42066137892022 @default.
• W4206613789 countsByYear W42066137892023 @default.
• W4206613789 crossrefType "reference-entry" @default.
• W4206613789 hasAuthorship W4206613789A9999999999 @default.
• W4206613789 hasConcept C121608353 @default.
• W4206613789 hasConcept C126322002 @default.
• W4206613789 hasConcept C143998085 @default.
• W4206613789 hasConcept C168563851 @default.
• W4206613789 hasConcept C2777176818 @default.
• W4206613789 hasConcept C2777863537 @default.
• W4206613789 hasConcept C29456083 @default.
• W4206613789 hasConcept C530470458 @default.
• W4206613789 hasConcept C535046627 @default.
• W4206613789 hasConcept C71924100 @default.
• W4206613789 hasConcept C95190672 @default.
• W4206613789 hasConceptScore W4206613789C121608353 @default.
• W4206613789 hasConceptScore W4206613789C126322002 @default.
• W4206613789 hasConceptScore W4206613789C143998085 @default.
• W4206613789 hasConceptScore W4206613789C168563851 @default.
• W4206613789 hasConceptScore W4206613789C2777176818 @default.
• W4206613789 hasConceptScore W4206613789C2777863537 @default.
• W4206613789 hasConceptScore W4206613789C29456083 @default.
• W4206613789 hasConceptScore W4206613789C530470458 @default.
• W4206613789 hasConceptScore W4206613789C535046627 @default.
• W4206613789 hasConceptScore W4206613789C71924100 @default.
• W4206613789 hasConceptScore W4206613789C95190672 @default.
• W4206613789 hasLocation W42066137891 @default.
• W4206613789 hasLocation W42066137892 @default.
• W4206613789 hasOpenAccess W4206613789 @default.
• W4206613789 hasPrimaryLocation W42066137891 @default.
• W4206613789 hasRelatedWork W169255034 @default.
• W4206613789 hasRelatedWork W1997906202 @default.
• W4206613789 hasRelatedWork W1999183598 @default.
• W4206613789 hasRelatedWork W2015092588 @default.
• W4206613789 hasRelatedWork W2090349639 @default.
• W4206613789 hasRelatedWork W2118728607 @default.
• W4206613789 hasRelatedWork W2172254302 @default.
• W4206613789 hasRelatedWork W2464051959 @default.
• W4206613789 hasRelatedWork W2769256842 @default.
• W4206613789 hasRelatedWork W4361808793 @default.
• W4206613789 isParatext "false" @default.
• W4206613789 isRetracted "false" @default.
• W4206613789 workType "reference-entry" @default.